CYP - don't know much about this mob, but they're researching in the stem-cell, transplant-rejection therapy space, occupied by the 8oo pound gorilla, Mesoblast (MSB).
Mesoblast is insanely overvalued, but CYP, at 40 mill market cap?
If biotechs were fashionable, this would surge, but they're not, so it probably won't, yet ... maybe ...
Expand
